Oncomine Dx Express Test
Life Technologies Corporation · Decision date Sep 9, 2026
What did the FDA approve?
This FDA record documents the September 9, 2026 approval of supplement S005 to PMA P240040 for Life Technologies Corporation. The supplement, filed under the Panel Track with a labeling-change reason, expands the approved indications for use to add a companion diagnostic indication. That indication covers detection of ERBB2/HER2 activating mutations, specified as single nucleotide variants in exons 18–21 within the tyrosine kinase domain plus exon 20 insertions, in patients with non-small cell lung cancer.
The changed item is the indications statement of the device, a next-generation sequencing oncology panel for somatic or germline variant detection under product code PQP and the Pathology specialty. The source statement links the added indication to identifying NSCLC patients who may benefit from treatment with HYRNUO (sevabertinib). This supplement modifies the existing P240040 approval rather than approving the whole system anew; the record does not describe the panel's other content, performance characteristics, or original scope beyond the identifier.
FDA approval order statement
Approval to expand the indications for use to include a companion diagnostic (CDx) indication for the detection of ERBB2/HER2 activating mutations (SNVs in exons 18-21 within the tyrosine kinase domain and exon 20 insertions) in patients with non-small cell lung cancer (NSCLC) who may benefit from treatment with HYRNUO (sevabertinib).
- Regulatory pathway
- PMA supplement
- Supplement type
- Panel Track
- Clinical specialty
- Pathology
- Decision date
- Sep 9, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P240040/S005
- Regulatory pathway
- PMA supplement
- Applicant
- Life Technologies Corporation
- Product code
- PQP
- Decision code
- APPR
- Decision date
- Sep 9, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.
- Applicant
- Life Technologies Corporation
- Product code
- PQP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240040. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240040 · Original PMA
Oncomine Dx Express Test
P240040/S005 received
Application receipt date recorded by FDA.
P240040/S005 · FDA decision
Panel Track
P240040/S008 · Related supplement
Oncomine Dx Express Test
Timeline entries are records held by MedtechLedger for P240040. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240040
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Oncomine Dx Express TestP240040 | Life Technologies Corporation | PMA approval | Jul 2, 2025 | FDA |
Oncomine Dx Express TestP240040/S008 | Life Technologies Corporation | PMA supplement | Nov 4, 2026 | FDA |
Explore the linked device profile
Other records with product code PQP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
xT CDxP210011/S006 | Tempus AI, Inc. | PMA supplement | Oct 23, 2026 | FDA |
MI Cancer SeekP240010/S007 | Caris Life Sciences | PMA supplement | Oct 16, 2026 | FDA |
FoundationOne Liquid CDx (F1LCDx)P190032/S032 | Foundation Medicine, Inc. | PMA supplement | Sep 18, 2026 | FDA |
Guardant360 CDxP200010/S029 | Guardant Health, Inc. | PMA supplement | Sep 18, 2026 | FDA |
FoundationOne CDxP170019/S069 | Foundation Medicine, Inc. | PMA supplement | Sep 16, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Life Technologies Corporation
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 7335 Executive Way, Frederick, MD, 21704
Sources and methodology
- Original FDA record: P240040/S005
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



